|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N03AX16
|
|
gptkbp:availableOn
|
capsule
oral solution
|
|
gptkbp:bioavailability
|
≥90%
|
|
gptkbp:brand
|
gptkb:Lyrica
|
|
gptkbp:CASNumber
|
gptkb:148553-50-8
|
|
gptkbp:chemicalClass
|
gabapentinoid
|
|
gptkbp:contraindication
|
hypersensitivity to pregabalin
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_V_(US)
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
1990
|
|
gptkbp:eliminationHalfLife
|
6.3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C8H17NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pregabalin
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:CNS_depressants
opioids
|
|
gptkbp:IUPACName
|
gptkb:(S)-3-(aminomethyl)-5-methylhexanoic_acid
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to α2δ subunit of voltage-gated calcium channels
|
|
gptkbp:meltingPoint
|
194–196 °C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:patentExpired
|
2018 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
<1%
|
|
gptkbp:PubChem_CID
|
gptkb:DB00230
gptkb:CHEMBL1488
5486971
|
|
gptkbp:riskFactor
|
abuse
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
dizziness
blurred vision
weight gain
dry mouth
somnolence
|
|
gptkbp:synonym
|
gptkb:CI-1008
gptkb:isobutyl_GABA
|
|
gptkbp:UNII
|
55JG375S6M
|
|
gptkbp:usedFor
|
gptkb:generalized_anxiety_disorder
epilepsy
peripheral neuropathy
fibromyalgia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Anti-Anxiety_Agents
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|